The COVID-19 pandemic highlighted the need for adaptable and scalable vaccine technologies. While mRNA vaccines have improved disease prevention, most are delivered by intramuscular injection, which may not effectively prevent infections that begin at mucosal surfaces, such as the nose and lungs. For respiratory pathogens, this limits protection at the initial site of infection.
Inhalable nanovaccines are being investigated as an alternative approach. These formulations are designed to activate immune responses in the respiratory tract, where pathogens often enter, by delivering antigens to local immune cells through mucosal immunization.
Mechanisms of Delivery: How Nanocarriers Work
Inhalable nanovaccines utilize engineered nanoparticles to deliver antigens or genetic material to immune cells in the respiratory tract. These nanocarriers are designed to overcome biological barriers, such as mucus layers and enzymatic degradation, while targeting antigen-presenting cells (APCs) like dendritic cells and alveolar macrophages to enhance immune activation.
Lipid Nanoparticles (LNPs)
LNPs, widely used in mRNA COVID-19 vaccines, are being adapted for inhalable delivery. Their formulation includes ionizable lipids, cholesterol, and polyethylene glycol (PEG), which protect messenger RNA (mRNA) and facilitate its uptake by cells.
A recent study in the Journal of the American Chemical Society demonstrated that modified LNPs remained stable during nebulization and successfully delivered mRNA to the lungs of mice, leading to uniform protein expression without inducing inflammation.1 An additional modification involving cationic lipids improved targeting of lung tissues.1,2
Polymer-Based and Biomimetic Systems
Polymeric nanoparticles, such as those made from polylactic-co-glycolic acid (PLGA), can be designed for controlled release and enhanced immune response. Researchers have also developed virus-like nanovaccines that mimic the structural features of pathogens.
One biomimetic COVID-19 vaccine combined pulmonary surfactant liposomes with SARS-CoV-2 spike proteins, promoting mucosal immunoglobulin A (IgA) responses in preclinical models. Similarly, mussel-inspired nanoparticles with mucoadhesive properties have shown promise in penetrating lung mucus to deliver anticancer drugs, a strategy adaptable for vaccines.3,4
Hybrid Nanoplatforms
Hybrid platforms combine synthetic and biological components to improve vaccine performance. One approach involved fusing nanovesicles expressing SARS-CoV-2 antigens with adjuvant-loaded liposomes. This formulation activated alveolar macrophages and led to the production of both systemic immunoglobulin G (IgG) and mucosal IgA, suggesting broader protection across different viral variants.5
Key Advantages of Inhalable Nanovaccines
Needle-Free Delivery
Inhalable vaccines avoid the risks associated with injections, including needle-related injuries and infections. They may also be more acceptable to people with needle phobia and are easier to administer in mass vaccination efforts. Convidecia Air, an inhalable COVID-19 vaccine approved in China, demonstrated high user acceptability.5
Inhalable formats could also support self-administration, which is especially relevant in regions with limited healthcare infrastructure.6
Unlike injectable vaccines, which mainly stimulate systemic IgG, inhalable vaccines promote the production of secretory immunoglobulin A (sIgA) at mucosal surfaces. sIgA helps neutralize pathogens before they can infect host cells, reducing transmission. A recent study published in Signal Transduction and Targeted Therapy showed that intranasal RNA vaccines can generate lung-resident memory T cells and sIgA, providing superior protection against respiratory viruses compared to intramuscular shots.2,6
Enhanced Stability and Distribution
Many nanovaccine platforms, including LNPs and polymer-based systems, can be freeze-dried (lyophilized), allowing storage at 4°C or lower without cold-chain dependency. For example, researchers at the University of Wisconsin-Madison developed a lyophilized avian influenza nanovaccine stable for 30 days at -20 °C, indicating its suitability for use in low-resource or remote settings.7
Current Research and Target Diseases
Recent advancements in inhalable nanovaccines are transforming disease prevention and treatment. Current targets include COVID-19, influenza, tuberculosis, and lung cancer.
COVID-19
Inhalable vaccine platforms have been applied extensively in COVID-19 research. Scientists have developed a hybrid nanovaccine that combines receptor-binding domain (RBD)-expressing nanovesicles with monophosphoryl lipid A (MPLA) adjuvant liposomes. This combination has been shown to elicit potent neutralizing antibodies against multiple variants, including Omicron, in preclinical models.
Additionally, a biomimetic vaccine designed to mimic the structure of the virus induced mucosal sIgA responses in mice that exceeded those generated by intramuscular vaccines.3,5
Influenza
Conventional influenza vaccines have limited efficacy due to frequent antigenic drift. Nanoparticle-based strategies aim to improve coverage by delivering conserved antigens or mosaic hemagglutinin (HA) proteins. A study from the University of Wisconsin–Madison developed a mosaic HA nanovaccine capable of eliciting cross-reactive immune responses in poultry against diverse high pathogenic avian influenza (HPAI) strains. This approach may be adaptable to human vaccination.7
Tuberculosis (TB)
TB primarily infects the lungs, making inhalable vaccines an ideal option. Studies have shown that PLGA nanoparticles loaded with Mycobacterium tuberculosis (Mtb) antigens can stimulate lung-resident immune cells, resulting in a greater reduction in bacterial load compared to injectable Bacillus Calmette-Guérin (BCG) vaccines.8
Lung Cancer
In addition to their potential for treating infections, inhalable nanovaccines are also being explored in oncology. Recent studies have shown that intranasal RNA vaccines encapsulated in lipid nanoparticles enhanced with cationic lipid 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) can reprogram cytotoxic T cells to target lung tumors in mice. This approach has doubled the survival rates in mice without causing systemic toxicity.2
Formulation Challenges and Innovations
Researchers are developing new strategies to address technical challenges associated with inhalable nanovaccine delivery, focusing on stability, lung retention, and immune safety.
Overcoming Mucosal Barriers
The lung’s mucus layer and mucociliary clearance rapidly remove inhaled particles. To address this, researchers developed nanoparticles with mucoadhesive surfaces, such as those coated with cysteine-modified mussel proteins, which prolong retention in the lungs.3
Stability During Nebulization
Nebulization can damage nanoparticles, reducing efficacy. A recent study published in the Journal of the American Chemical Society solved this by incorporating zwitterionic polymers into LNPs, which prevented aggregation and maintained mRNA integrity during aerosolization.1
Balancing Immunogenicity and Safety
While adjuvants such as MPLA enhance immune responses, excessive activation can lead to inflammation. Hybrid nanovaccines using pH-sensitive polymers have been developed to provide more controlled adjuvant release, aiming to avoid excessive cytokine responses while preserving efficacy.5
The Future of Inhalable Nanovaccines
Future research will likely see inhalable nanovaccines targeting a broader range of diseases, from RSV to antimicrobial-resistant pathogens. Emerging directions include the use of AI-based models to optimize nanoparticle design, multivalent formulations that deliver several antigens simultaneously, and thermostable formulations in powder form to support use in low-resource or emergency settings.7,8
Inhalable nanovaccines represent an evolving area of vaccine technology. By enabling mucosal immune responses and offering needle-free administration, they may expand access to immunization and improve outcomes for respiratory diseases. Although formulation and distribution challenges remain, continued research and cross-sector collaboration may support the broader implementation of inhalable vaccine platforms as part of future public health strategies.
If you want to learn more about inhalable nanovaccines and related advances in drug delivery, immunology, and nanotechnology, subscribe to our expert-curated Nanomedicine Newsletter.
References and Further Reading
- Jiang, A. Y. et al. (2024). Zwitterionic Polymer-Functionalized Lipid Nanoparticles for the Nebulized Delivery of mRNA. Journal of the American Chemical Society. DOI:10.1021/jacs.4c11347. https://pubs.acs.org/doi/full/10.1021/jacs.4c11347
- Li, H. et al. (2025). Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy. Signal Transduction and Targeted Therapy, 10(1), 1-15. DOI:10.1038/s41392-025-02191-1. https://www.nature.com/articles/s41392-025-02191-1
- Zheng, B. et al. (2021). Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19. Chemical Engineering Journal, 418, 129392. DOI:10.1016/j.cej.2021.129392. https://www.sciencedirect.com/science/article/pii/S1385894721009803
- Inhalable therapy uses mussel-inspired nanoparticles to target lung cancer cells. (2025). Phys.org. https://phys.org/news/2025-01-inhalable-therapy-mussel-nanoparticles-lung.html
- Wang, S. et al. (2024). Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants. Journal of Nanobiotechnology, 22, 76. DOI:10.1186/s12951-024-02345-3. https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-024-02345-3
- Kiyono, H., & Ernst, P. B. (2025). Nasal vaccines for respiratory infections. Nature, 641(8062), 321-330. DOI:10.1038/s41586-025-08910-6. https://www.nature.com/articles/s41586-025-08910-6
- Sukumaran, P. (2025). Novel NanoVaccines Against Emerging Isolates of Avian Influenza. Nanovaccine Institute, Iowa State University. https://nanovaccine.iastate.edu/novel-nanovaccines-against-emerging-isolates-of-avian-influenza/
- Saleh, M. et al. (2025). Revolutionizing Nanovaccines: A New Era of Immunization. Vaccines, 13(2), 126. DOI:10.3390/vaccines13020126. https://www.mdpi.com/2076-393X/13/2/126
News
Researchers propose five key questions for effective adoption of AI in clinical practice
While Artificial Intelligence (AI) can be a powerful tool that physicians can use to help diagnose their patients and has great potential to improve accuracy, efficiency and patient safety, it has its drawbacks. It [...]
Advancements and clinical translation of intelligent nanodrugs for breast cancer treatment
A comprehensive review in "Biofunct. Mater." meticulously details the most recent advancements and clinical translation of intelligent nanodrugs for breast cancer treatment. This paper presents an exhaustive overview of subtype-specific nanostrategies, the clinical benefits [...]
It’s Not “All in Your Head”: Scientists Develop Revolutionary Blood Test for Chronic Fatigue Syndrome
A 96% accurate blood test for ME/CFS could transform diagnosis and pave the way for future long COVID detection. Researchers from the University of East Anglia and Oxford Biodynamics have created a highly accurate [...]
How Far Can the Body Go? Scientists Find the Ultimate Limit of Human Endurance
Even the most elite endurance athletes can’t outrun biology. A new study finds that humans hit a metabolic ceiling at about 2.5 times their resting energy burn. When ultra-runners take on races that last [...]
World’s Rivers “Overdosing” on Human Antibiotics, Study Finds
Researchers estimate that approximately 8,500 tons of antibiotics enter river systems each year after passing through the human body and wastewater treatment processes. Rivers spanning millions of kilometers across the globe are contaminated with [...]
Yale Scientists Solve a Century-Old Brain Wave Mystery
Yale scientists traced gamma brain waves to thalamus-cortex interactions. The discovery could reveal how brain rhythms shape perception and disease. For more than a century, scientists have observed rhythmic waves of synchronized neuronal activity [...]
Can introducing peanuts early prevent allergies? Real-world data confirms it helps
New evidence from a large U.S. primary care network shows that early peanut introduction, endorsed in 2015 and 2017 guidelines, was followed by a marked decline in clinician-diagnosed peanut and overall food allergies among [...]
Nanoparticle blueprints reveal path to smarter medicines
Lipid nanoparticles (LNPs) are the delivery vehicles of modern medicine, carrying cancer drugs, gene therapies and vaccines into cells. Until recently, many scientists assumed that all LNPs followed more or less the same blueprint, [...]
How nanomedicine and AI are teaming up to tackle neurodegenerative diseases
When I first realized the scale of the challenge posed by neurodegenerative diseases, such as Alzheimer's, Parkinson's disease and amyotrophic lateral sclerosis (ALS), I felt simultaneously humbled and motivated. These disorders are not caused [...]
Self-Organizing Light Could Transform Computing and Communications
USC engineers have demonstrated a new kind of optical device that lets light organize its own route using the principles of thermodynamics. Instead of relying on switches or digital control, the light finds its own [...]
Groundbreaking New Way of Measuring Blood Pressure Could Save Thousands of Lives
A new method that improves the accuracy of interpreting blood pressure measurements taken at the ankle could be vital for individuals who are unable to have their blood pressure measured on the arm. A newly developed [...]
Scientist tackles key roadblock for AI in drug discovery
The drug development pipeline is a costly and lengthy process. Identifying high-quality "hit" compounds—those with high potency, selectivity, and favorable metabolic properties—at the earliest stages is important for reducing cost and accelerating the path [...]
Nanoplastics with environmental coatings can sneak past the skin’s defenses
Plastic is ubiquitous in the modern world, and it's notorious for taking a long time to completely break down in the environment - if it ever does. But even without breaking down completely, plastic [...]
Chernobyl scientists discover black fungus feeding on deadly radiation
It looks pretty sinister, but it might actually be incredibly helpful When reactor number four in Chernobyl exploded, it triggered the worst nuclear disaster in history, one which the surrounding area still has not [...]
Long COVID Is Taking A Silent Toll On Mental Health, Here’s What Experts Say
Months after recovering from COVID-19, many people continue to feel unwell. They speak of exhaustion that doesn’t fade, difficulty breathing, or an unsettling mental haze. What’s becoming increasingly clear is that recovery from the [...]
Study Delivers Cancer Drugs Directly to the Tumor Nucleus
A new peptide-based nanotube treatment sneaks chemo into drug-resistant cancer cells, providing a unique workaround to one of oncology’s toughest hurdles. CiQUS researchers have developed a novel molecular strategy that allows a chemotherapy drug to [...]
